Spruce Biosciences (SPRB) is nearing pivotal data releases from its ongoing clinical trials of Tildacerfont, an investigational therapy for Congenital Adrenal Hyperplasia.
Tildacerfont is a non-steroidal, oral second-generation CRF1 receptor antagonist, being developed to treat patients with classic congenital adrenal hyperplasia (CAH) and other diseases characterized by elevated levels of adrenocorticotropic hormone.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.